Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
432 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02399085 | Open Label Study to Evaluate the Safety and Efficacy of Lenalidomide With MOR00208 in Patients With R-R DLBCL(L-MIND) | completed | Phase 2 | 81 | MorphoSys AGINDUSTRY | 10 | Oct 23, 2023 | clinicaltrials |
| NCT04045613 | Derazantinib and Atezolizumab in Patients With Urothelial Cancer(FIDES-02) | completed | Phase 1 / Phase 2 | 95 | Basilea PharmaceuticaINDUSTRY | 14 | Oct 13, 2023 |
| clinicaltrials |
| NCT01485861 | Study of Ipatasertib or Apitolisib With Abiraterone Acetate Versus Abiraterone Acetate in Participants With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy | completed | Phase 1 / Phase 2 | 298 | Genentech, Inc.INDUSTRY | 9 | Sep 14, 2023 | clinicaltrials |
| NCT02499120 | Safety And Efficacy Study Of Palbociclib Plus Cetuximab Versus Cetuximab To Treat Head And Neck Cancer | completed | Phase 2 | 125 | PfizerINDUSTRY | 15 | Sep 8, 2023 | clinicaltrials |
| NCT03826628 | Dose-Ranging Efficacy and Safety Study of Topical Rapamycin Cream for Facial Angiofibroma Associated With Tuberous Sclerosis Complex | completed | Phase 2 / Phase 3 | 107 | Dermatology Specialties Limited PartnershipINDUSTRY | 9 | Sep 8, 2023 | clinicaltrials |
| NCT01882803 | A Study of Duvelisib in Participants With Refractory Indolent Non-Hodgkin Lymphoma(DYNAMO) | completed | Phase 2 | 129 | SecuraBioINDUSTRY | 12 | Sep 7, 2023 | clinicaltrials |
| NCT03317496 | Safety And Efficacy Study Of Avelumab Plus Chemotherapy With Or Without Other Anti-Cancer Immunotherapy Agents In Patients With Advanced Malignancies | terminated | Phase 1 / Phase 2 | 67 | PfizerINDUSTRY | 8 | Aug 29, 2023 | clinicaltrials |
| NCT03200717 | Study of Efficacy, Safety, and Quality of Life of Pazopanib in Patients With Advanced and/or Metastatic Renal Cell Carcinoma After Prior Checkpoint Inhibitor Treatment(IO-PAZ) | completed | Phase 2 | 62 | Novartis PharmaceuticalsINDUSTRY | 11 | Aug 21, 2023 | clinicaltrials |
| NCT02614794 | A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer(HER2CLIMB) | completed | Phase 2 | 612 | Seagen Inc.INDUSTRY | 15 | Aug 14, 2023 | clinicaltrials |
| NCT00542308 | Zalutumumab in Non-curable Patients With SCCHN | completed | Phase 2 | 90 | GenmabINDUSTRY | 11 | Aug 3, 2023 | clinicaltrials |
| NCT03438396 | A Trial of Tisotumab Vedotin in Cervical Cancer | completed | Phase 2 | 102 | Seagen Inc.INDUSTRY | 8 | Jul 25, 2023 | clinicaltrials |
| NCT03637764 | Safety, Preliminary Efficacy and PK of Isatuximab (SAR650984) Alone or in Combination With Atezolizumab in Patients With Advanced Malignancies | terminated | Phase 1 / Phase 2 | 107 | SanofiINDUSTRY | 8 | Jul 10, 2023 | clinicaltrials |
| NCT01126736 | Eribulin Mesylate Administered in Combination With Pemetrexed Versus Pemetrexed Alone as Second Line Therapy in Patients With Stage IIIB or IV Nonsquamous Non Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 98 | Eisai Inc.INDUSTRY | 5 | Jun 22, 2023 | clinicaltrials |
| NCT01593254 | Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who Did Not Have Favorable Response to Imatinib(DASCERN) | completed | Phase 2 | 262 | Bristol-Myers SquibbINDUSTRY | 15 | Jun 22, 2023 | clinicaltrials |
| NCT02823574 | Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck(CheckMate 714) | completed | Phase 2 | 425 | Bristol-Myers SquibbINDUSTRY | 21 | May 3, 2023 | clinicaltrials |
| NCT03639610 | PK of Melphalan During Treatment With Melflufen and Dexamethasone in Patients With RRMM and Impaired Renal Function(BRIDGE) | terminated | Phase 2 | 35 | Oncopeptides ABINDUSTRY | 3 | Mar 10, 2023 | clinicaltrials |
| NCT03312530 | A Study of Cobimetinib Administered as Single Agent and in Combination With Venetoclax, With or Without Atezolizumab, in Participants With Relapsed and Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 49 | Hoffmann-La RocheINDUSTRY | 9 | Feb 28, 2023 | clinicaltrials |
| NCT01625286 | Investigating Safety, Tolerability and Efficacy of AZD5363 When Combined With Paclitaxel in Breast Cancer Patients(BEECH) | completed | Phase 1 / Phase 2 | 148 | AstraZenecaINDUSTRY | 11 | Jan 18, 2023 | clinicaltrials |
| NCT04515394 | Study of Tepotinib Combined With Cetuximab in Participants With Left-Sided RAS/BRAF Wild Type Metastatic Colorectal Cancer (PERSPECTIVE) | terminated | Phase 2 | 3 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 8 | Dec 22, 2022 | clinicaltrials |
| NCT03170882 | A Study of Ixazomib, Given With Dexamethasone in Adults With Multiple Myeloma | completed | Phase 2 | 122 | Millennium Pharmaceuticals, Inc.INDUSTRY | 18 | Dec 20, 2022 | clinicaltrials |
| NCT03481556 | Study of Melphalan Flufenamide (Melflufen) + Dex With Bortezomib or Daratumumab in Patients With RRMM(ANCHOR) | terminated | Phase 1 / Phase 2 | 56 | Oncopeptides ABINDUSTRY | 4 | Dec 19, 2022 | clinicaltrials |
| NCT03980041 | Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275) | completed | Phase 2 | 49 | Infinity Pharmaceuticals, Inc.INDUSTRY | 7 | Nov 25, 2022 | clinicaltrials |
| NCT02257567 | A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma | completed | Phase 1 / Phase 2 | 331 | Hoffmann-La RocheINDUSTRY | 13 | Nov 14, 2022 | clinicaltrials |
| NCT02387996 | A Study of Nivolumab in Participants With Metastatic or Unresectable Bladder Cancer | completed | Phase 2 | 270 | Bristol-Myers SquibbINDUSTRY | 11 | Nov 1, 2022 | clinicaltrials |
| NCT02917772 | Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Renal Cell Carcinoma(TITAN-RCC) | completed | Phase 2 | 200 | AIO-Studien-gGmbHOTHER | 8 | Oct 6, 2022 | clinicaltrials |
| NCT03410693 | Study of Rogaratinib (BAY1163877) vs Chemotherapy in Patients With FGFR (Fibroblast Growth Factor Receptor)-Positive Locally Advanced or Metastatic Urothelial Carcinoma(FORT-1) | completed | Phase 2 / Phase 3 | 175 | BayerINDUSTRY | 29 | Sep 28, 2022 | clinicaltrials |
| NCT02610777 | An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML) | completed | Phase 2 | 120 | Millennium Pharmaceuticals, Inc.INDUSTRY | 12 | Sep 19, 2022 | clinicaltrials |
| NCT02370238 | A Double-blind Study of Paclitaxel in Combination With Reparixin or Placebo for Metastatic Triple-Negative Breast Cancer(FRIDA) | completed | Phase 2 | 194 | Dompé Farmaceutici S.p.AINDUSTRY | 7 | Sep 16, 2022 | clinicaltrials |
| NCT02432846 | Intratumoral Vaccination With Intuvax Pre-nephrectomy Followed by Sunitinib Post-nephrectomy vs Sunitinib Post-nephrectomy in Newly Diagnosed Metastatic Renal Cell Carcinoma (mRCC)(MERECA) | completed | Phase 2 | 88 | MendusINDUSTRY | 9 | Aug 22, 2022 | clinicaltrials |
| NCT04529850 | Ph 2 Open Label Study of GC4419 to Reduce SOM Associated With Chemoradiotherapy for Head and Neck Cancer | completed | Phase 2 | 38 | Galera Therapeutics, Inc.INDUSTRY | 6 | Aug 16, 2022 | clinicaltrials |
| NCT04502394 | Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL | recruiting | Phase 1 / Phase 2 | 84 | Kartos Therapeutics, Inc.INDUSTRY | 11 | Aug 4, 2022 | clinicaltrials |
| NCT00573131 | Efficacy and Safety of OncoGel™ Added to Chemotherapy and Radiation Before Surgery in Subjects With Esophageal Cancer | terminated | Phase 2 | 137 | Boston Scientific CorporationINDUSTRY | 4 | Jun 22, 2022 | clinicaltrials |
| NCT03738423 | Efficacy, Safety, and Pharmacokinetic Profiles of REGN3500 Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis | terminated | Phase 2 | 129 | Regeneron PharmaceuticalsINDUSTRY | 11 | Jun 10, 2022 | clinicaltrials |
| NCT00676663 | Study to Evaluate Exemestane With and Without Entinostat (SNDX-275) in Treatment of Postmenopausal Women With Advanced Breast Cancer(ENCORE301) | completed | Phase 2 | 130 | Syndax PharmaceuticalsINDUSTRY | 5 | May 11, 2022 | clinicaltrials |
| NCT02107937 | Phase II Study DCVAC/OvCa Added to First Line Carboplatin and Paclitaxel Newly Diagnosed Epithelial Ovarian Carcinoma | completed | Phase 2 | 136 | SOTIO a.s.INDUSTRY | 2 | May 4, 2022 | clinicaltrials |
| NCT02470468 | Evaluation of Safety and Efficacy of DCVAC/LuCa (Immunotherapy of Lung Cancer) in Patients With Metastatic Lung Cancer | completed | Phase 1 / Phase 2 | 105 | SOTIO a.s.INDUSTRY | 2 | May 4, 2022 | clinicaltrials |
| NCT03799731 | Study for Evaluation of Murlentamab (GM102) Anti-tumoral Activity in Colorectal Cancers | completed | Phase 2 | 65 | GamaMabs PharmaINDUSTRY | 2 | Apr 14, 2022 | clinicaltrials |
| NCT02850419 | Heat-Activated Target Therapy of Local-Regional Relapse in Breast Cancer Patients(EURO-DIGNITY) | withdrawn | Phase 2 | 0 | ImunonINDUSTRY | 3 | Apr 7, 2022 | clinicaltrials |
| NCT04097301 | Study of CAR T-cell Therapy in Acute Myeloid Leukemia and Multiple Myeloma | terminated | Phase 1 / Phase 2 | 8 | AGC Biologics S.p.A.INDUSTRY | 2 | Jan 19, 2022 | clinicaltrials |
| NCT02857426 | A Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Relapsed/Refractory Primary Testicular Lymphoma (PTL)(CheckMate 647) | completed | Phase 2 | 66 | Bristol-Myers SquibbINDUSTRY | 13 | Dec 23, 2021 | clinicaltrials |
| NCT02724020 | MLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adults With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma | completed | Phase 2 | 96 | Millennium Pharmaceuticals, Inc.INDUSTRY | 8 | Nov 19, 2021 | clinicaltrials |
| NCT03736967 | Efficacy and Safety of REGN3500 Monotherapy and Combination of REGN3500 Plus Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis | terminated | Phase 2 | 206 | Regeneron PharmaceuticalsINDUSTRY | 7 | Nov 1, 2021 | clinicaltrials |
| NCT01951586 | Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer | completed | Phase 2 | 226 | AmgenINDUSTRY | 10 | Oct 25, 2021 | clinicaltrials |
| NCT02984683 | Study Evaluating Efficacy and Safety of SAR566658 Treatment in Patients With CA6 Positive Metastatic Triple Negative Breast Cancer | terminated | Phase 2 | 23 | SanofiINDUSTRY | 5 | Sep 8, 2021 | clinicaltrials |
| NCT05006664 | Brentuximab Vedotin in Combination With CHEP in Patient With PTCL | unknown | Phase 2 | 33 | Czech Lymphoma Study GroupOTHER | 1 | Sep 1, 2021 | clinicaltrials |
| NCT03136653 | A Phase 2 Trial of MP0250 Plus Bortezomib + Dexamethasone in Patients With Multiple Myeloma | completed | Phase 1 / Phase 2 | 33 | Molecular Partners AGINDUSTRY | 6 | Aug 25, 2021 | clinicaltrials |
| NCT03052751 | Study to Test the Safety, Tolerability and Efficacy of UCB7665 in Subjects With Moderate to Severe Myasthenia Gravis | completed | Phase 2 | 43 | UCB Biopharma S.P.R.L.INDUSTRY | 7 | Aug 3, 2021 | clinicaltrials |
| NCT02216578 | Ph II CABOGIST in GIST | completed | Phase 2 | 51 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 6 | Jul 15, 2021 | clinicaltrials |
Data updated 22 days agoSource updated unknownsource: clinicaltrials